<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9099377</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">35572148</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">9099377</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.3389/fnagi.2022.881311</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>TABLE 1</table-label><table-caption>Trial registration data.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="T1"><label>TABLE 1</label><caption><p>Trial registration data.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Data category</td><td valign="top" align="left" rowspan="1" colspan="1">Trial information</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Primary registry and trial identifying number</td><td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2100052590</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Date of registration in primary registry</td><td valign="top" align="left" rowspan="1" colspan="1">27 October 2021</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Secondary identifying numbers</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Source(s) of monetary or material support</td><td valign="top" align="left" rowspan="1" colspan="1">This project is being supported by Wuxi Taihu Talent Project (WXTTP2020008), the Nanjing Municipal Science and Technology Bureau (2019060002), the Major Scientific Research Project of Wuxi Health Committee (Z202013), Top Talent Support Program for Young and Middle-Aged People of Wuxi Health Committee (HB2020079), Scientific and Technological Development Fund from Wuxi Science and Technology Bureau (Y20212008), Wuxi Municipal Health Commission Scientific Project (T201144), and Jiangsu Geriatrics Clinical Technology Application Research Project (LR2021040).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Primary sponsor</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Secondary sponsor(s)</td><td valign="top" align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Contact for public queries</td><td valign="top" align="left" rowspan="1" colspan="1">Bin Su, <email>13951585359@163.com</email></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Contact for scientific queries</td><td valign="top" align="left" rowspan="1" colspan="1">Bin Su, <email>13951585359@163.com</email></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Public title</td><td valign="top" align="left" rowspan="1" colspan="1">Effect of cerebellar vermis iTBS on the balance dysfunction of stroke patients and the brain remodeling mechanism</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Scientific title</td><td valign="top" align="left" rowspan="1" colspan="1">Effect of cerebellar vermis iTBS on the balance dysfunction of stroke patients and the brain remodeling mechanism</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Countries of recruitment</td><td valign="top" align="left" rowspan="1" colspan="1">China</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Healthy conditions(s) or problem(s) studied</td><td valign="top" align="left" rowspan="1" colspan="1">Stroke with hemiparesis, including balance dysfunction</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervention(s)</td><td valign="top" align="left" rowspan="1" colspan="1">Active comparator: iTBS (application of 600 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 200 s) will be applied to the cerebellum vermis positioned tangentially to the scalp combined with routine rehabilitation treatment.<break/> Sham comparator: Sham stimulus will be applied to same location with a customized sham coil, also combined with routine rehabilitation treatment.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Key inclusion and exclusion criteria</td><td valign="top" align="left" rowspan="1" colspan="1">Inclusion criteria: (a) have a diagnosis of stroke confirmed by CT and/or MRI, (b) have their first-ever unilateral ischemic stroke between 1 and 6 months of onset, (c) are 40–75 years old, (d) presented with a balance dysfunction with a Berg score between 0 and 40, (e) can follow simple verbal commands or instructions, and (f) can cooperate in signing informed consent forms.<break/> Exclusion criteria: (a) with contraindications involving TMS and fMRI (e.g., intracranial implant, cardiac pacemaker, implanted drug pumps, and pregnancy), (b) with cerebellum or brainstem stroke, (c) with balance dysfunction before stroke, (d) with serious diseases that may contribute to condition progression, (e) with severe deficits in communication or executing commands that prevent cooperation with assessment and treatment, (f) who are taking psychotropic drugs, and (g) who are currently enrolled in other clinical trials.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Study type</td><td valign="top" align="left" rowspan="1" colspan="1">Interventional<break/> Allocation: randomized intervention model<break/> Masking: participants and assessors-blinded<break/> Assignment: parallel<break/> Primary purpose: treatment</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Date of first enrolment</td><td valign="top" align="left" rowspan="1" colspan="1">Not yet started</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Target sample size</td><td valign="top" align="left" rowspan="1" colspan="1">40</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recruitment status</td><td valign="top" align="left" rowspan="1" colspan="1">Recruiting</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Primary outcome(s)</td><td valign="top" align="left" rowspan="1" colspan="1">Berg balance scale</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Key secondary outcome(s)</td><td valign="top" align="left" rowspan="1" colspan="1">Lower extremity of the Fugl–Meyer assessment; modified Barthel index; regional homogeneity, fractional amplitude of low frequency fluctuation and functional connectivity analyses from rs-fMRI.</td></tr></tbody></table></table-wrap></original-table><transformed-table>TABLE 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Trial registration data.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left">Data category</td><td valign="top" align="left">Trial information</td></tr></thead><tbody><tr><td valign="top" align="left">Primary registry and trial identifying number</td><td valign="top" align="left">ChiCTR2100052590</td></tr><tr><td valign="top" align="left">Date of registration in primary registry</td><td valign="top" align="left">27 October 2021</td></tr><tr><td valign="top" align="left">Secondary identifying numbers</td><td valign="top" align="left">N/A</td></tr><tr><td valign="top" align="left">Source(s) of monetary or material support</td><td valign="top" align="left">This project is being supported by Wuxi Taihu Talent Project (WXTTP2020008), the Nanjing Municipal Science and Technology Bureau (2019060002), the Major Scientific Research Project of Wuxi Health Committee (Z202013), Top Talent Support Program for Young and Middle-Aged People of Wuxi Health Committee (HB2020079), Scientific and Technological Development Fund from Wuxi Science and Technology Bureau (Y20212008), Wuxi Municipal Health Commission Scientific Project (T201144), and Jiangsu Geriatrics Clinical Technology Application Research Project (LR2021040).</td></tr><tr><td valign="top" align="left">Primary sponsor</td><td valign="top" align="left">N/A</td></tr><tr><td valign="top" align="left">Secondary sponsor(s)</td><td valign="top" align="left">N/A</td></tr><tr><td valign="top" align="left">Contact for public queries</td><td valign="top" align="left">Bin Su, <code class="email">&lt;<a class="email" href="mailto:13951585359@163.com">13951585359@163.com</a>&gt;</code></td></tr><tr><td valign="top" align="left">Contact for scientific queries</td><td valign="top" align="left">Bin Su, <code class="email">&lt;<a class="email" href="mailto:13951585359@163.com">13951585359@163.com</a>&gt;</code></td></tr><tr><td valign="top" align="left">Public title</td><td valign="top" align="left">Effect of cerebellar vermis iTBS on the balance dysfunction of stroke patients and the brain remodeling mechanism</td></tr><tr><td valign="top" align="left">Scientific title</td><td valign="top" align="left">Effect of cerebellar vermis iTBS on the balance dysfunction of stroke patients and the brain remodeling mechanism</td></tr><tr><td valign="top" align="left">Countries of recruitment</td><td valign="top" align="left">China</td></tr><tr><td valign="top" align="left">Healthy conditions(s) or problem(s) studied</td><td valign="top" align="left">Stroke with hemiparesis, including balance dysfunction</td></tr><tr><td valign="top" align="left">Intervention(s)</td><td valign="top" align="left">Active comparator: iTBS (application of 600 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 200 s) will be applied to the cerebellum vermis positioned tangentially to the scalp combined with routine rehabilitation treatment. Sham comparator: Sham stimulus will be applied to same location with a customized sham coil, also combined with routine rehabilitation treatment.</td></tr><tr><td valign="top" align="left">Key inclusion and exclusion criteria</td><td valign="top" align="left">Inclusion criteria: (a) have a diagnosis of stroke confirmed by CT and/or MRI, (b) have their first-ever unilateral ischemic stroke between 1 and 6 months of onset, (c) are 40–75 years old, (d) presented with a balance dysfunction with a Berg score between 0 and 40, (e) can follow simple verbal commands or instructions, and (f) can cooperate in signing informed consent forms. Exclusion criteria: (a) with contraindications involving TMS and fMRI (e.g., intracranial implant, cardiac pacemaker, implanted drug pumps, and pregnancy), (b) with cerebellum or brainstem stroke, (c) with balance dysfunction before stroke, (d) with serious diseases that may contribute to condition progression, (e) with severe deficits in communication or executing commands that prevent cooperation with assessment and treatment, (f) who are taking psychotropic drugs, and (g) who are currently enrolled in other clinical trials.</td></tr><tr><td valign="top" align="left">Study type</td><td valign="top" align="left">Interventional Allocation: randomized intervention model Masking: participants and assessors-blinded Assignment: parallel Primary purpose: treatment</td></tr><tr><td valign="top" align="left">Date of first enrolment</td><td valign="top" align="left">Not yet started</td></tr><tr><td valign="top" align="left">Target sample size</td><td valign="top" align="left">40</td></tr><tr><td valign="top" align="left">Recruitment status</td><td valign="top" align="left">Recruiting</td></tr><tr><td valign="top" align="left">Primary outcome(s)</td><td valign="top" align="left">Berg balance scale</td></tr><tr><td valign="top" align="left">Key secondary outcome(s)</td><td valign="top" align="left">Lower extremity of the Fugl–Meyer assessment; modified Barthel index; regional homogeneity, fractional amplitude of low frequency fluctuation and functional connectivity analyses from rs-fMRI.</td></tr></tbody></table></div></transformed-table></extracted-table></extracted-tables-set>